1-(aminomethyl)-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-ol | 87063-12-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 1-(aminomethyl)-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-ol
• 英文别名: 1-Aminomethyl-6-methoxy-1,2,3,4-tetrahydro-[1]naphthol；1-aminomethyl-1-hydroxy-6-methoxy-1,2,3,4-tetrahydronaphthalene；1-(aminomethyl)-6-methoxy-3,4-dihydro-2H-naphthalen-1-ol
• CAS: 87063-12-5
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: XCTAJOGFZVNQAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(aminomethyl)-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-ol 在 sodium nitrite 作用下， 生成 2-methoxy-5,7,8,9-tetrahydrobenzocyclohepten-6-one
  参考文献：
  名称：

  Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 2: substituted benzo[a]cycloheptene derivatives

  摘要：

  Novel berizo[a]cycloheptene derivatives were prepared for the purpose of searching new neuropeptide Y-Y5 (NPY-Y5) receptor antagonists, The structure activity relationships Lire described and compound 2o (FR226928) showed the most potent affinity for Y5 receptor of all we prepared and was found to have higher potency and better selectivity for Y5 over Y1 receptor affinities when compared with the known lead compound 1. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00002-1
• 作为产物：
  描述：

  6-methoxy-1-(trimethylsilanyloxy)-1,2,3,4-tetrahydronaphthalene-1-carbonitrile 在 lithium aluminium tetrahydride 作用下， 生成 1-(aminomethyl)-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-ol
  参考文献：
  名称：

  一种稳定的，非芳族的，从加合物“衍生本位” -nitration

  摘要：

  硝化N -[（6-甲氧基-1,2,3,4-四氢萘-1-基）甲基]丙酰胺（5）不仅得到预期的产物（6）和（7），而且得到三环加合物（8）），其结构通过单晶X射线分析确定。

  DOI：

  10.1039/c39830001046

文献信息

• [EN] HISTONE DEMETHYLASE INHIBITORS<br/>[FR] INHIBITEURS D'HISTONE DÉMÉTHYLASE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2014100818A1

  公开（公告）日：2014-06-26

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明一般涉及治疗癌症和肿瘤性疾病的组合物和方法。本文提供了取代的吡啶或吡啶二氮杂环衍生物化合物和包含该化合物的药物组合物。所述化合物和组合物可用于抑制组蛋白去甲基化酶。此外，所述化合物和组合物可用于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。
• Aminoalkyl dihydronaphthalenes
  申请人：Abbott Laboratories

  公开号：US04473586A1

  公开（公告）日：1984-09-25

  Disclosed herein are 1-aminoalkyl-3,4-dihydronaphthalenes represented by the formula ##STR1## wherein n is 1 or 2; R, R.sub.1, and R.sub.2 are independently selected from hydrogen, hydroxy, loweralkoxy of 1 to 3 carbon atoms, loweralkenyloxy of 1 to 3 carbon atoms, thiomethyl, halo, or ##STR2## wherein R.sub.5 and R.sub.6 are independently selected from hydrogen, loweracyl of 1 to 4 carbon atoms or sulfonyl of the formula ##STR3## wherein R.sub.7 is loweralkyl of 1 to 4 carbon atoms; or R and R.sub.1, or R.sub.1 and R.sub.2 can be taken together to form a methylenedioxy or ethylenedioxy bridge; with the proviso that at least one of R, R.sub.1 or R.sub.2 must be other than hydrogen; and R.sub.3 and R.sub.4 are independently selected from hydrogen; loweralkyl of 1 to 4 carbon atoms; halo-substituted loweralkyl of 1 to 4 carbon atoms; arylalkyl of the formula ##STR4## wherein m is 0, 1 or 2, p is 0 or 1, R.sub.8 is hydrogen or loweralkyl of 1 to 4 carbon atoms and R.sub.9 and R.sub.10 are independently selected from hydrogen, hydroxy, methoxy, loweralkyl of 1 to 4 carbon atoms, or halo, or R.sub.9 and R.sub.10 can be taken together to form a methylenedioxy or ethylenedioxy bridge; or 1,4-benzodioxan of the formula ##STR5## wherein q is 1, 2 or 3, and R.sub.11 is hydrogen, methoxy, or halo; or R.sub.3 and R.sub.4 can be taken together to form a piperazino, piperidino or morpholino moiety; and the pharmaceutically acceptable salts thereof. Also disclosed are novel intermediates useful in the preparation of these compounds.

  本公开涉及由下式表示的1-氨基烷基-3,4-二氢萘烯衍生物，其中n为1或2；R、R.sub.1和R.sub.2分别选自氢、羟基、1至3个碳原子的低烷氧基、1至3个碳原子的低烯氧基、硫甲基、卤素，或下式中的其中一种：其中R.sub.5和R.sub.6分别选自氢、1至4个碳原子的低酰基或下式的磺酰基：其中R.sub.7为1至4个碳原子的低烷基；或R和R.sub.1，或R.sub.1和R.sub.2可结合形成亚甲二氧桥或乙烯二氧桥；但R、R.sub.1或R.sub.2中至少有一个必须为氢以外的其他基团；R.sub.3和R.sub.4分别选自氢、1至4个碳原子的低烷基、1至4个碳原子的卤素取代的低烷基、下式的芳基烷基：其中m为0、1或2，p为0或1，R.sub.8为氢或1至4个碳原子的低烷基，R.sub.9和R.sub.10分别选自氢、羟基、甲氧基、1至4个碳原子的低烷基或卤素，或R.sub.9和R.sub.10可结合形成亚甲二氧桥或乙烯二氧桥；或下式的1,4-苯二氧杂环己烷：其中q为1、2或3，R.sub.11为氢、甲氧基或卤素；或R.sub.3和R.sub.4可结合形成哌嗪基、哌啶基或吗啉基；以及其药用盐。还公开了用于制备这些化合物的新型中间体。
• A stable, non-aromatic, adduct derived from ‘ipso’-nitration
  作者：Nigel R. A. Beeley、Gérard Cremer、Alain Dorlhène、Bernard Mompon、Claudine Pascard、Elise Tran Huu Dau

  DOI：10.1039/c39830001046

  日期：——

  Nitration of N-[(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)methyl]propanamide (5) gave not only the expected products (6) and (7) but also the tricyclic adduct (8), the structure of which was confirmed by a single crystal X-ray analysis.

  硝化N -[（6-甲氧基-1,2,3,4-四氢萘-1-基）甲基]丙酰胺（5）不仅得到预期的产物（6）和（7），而且得到三环加合物（8）），其结构通过单晶X射线分析确定。
• HISTONE DEMETHYLASE INHIBITORS
  申请人：Quanticel Pharmaceuticals, Inc.

  公开号：US20150119397A1

  公开（公告）日：2015-04-30

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明涉及治疗癌症和肿瘤疾病的组合物和方法。本发明提供了取代的酰胺吡啶或酰胺吡嗪衍生物化合物和含有该化合物的制药组合物。所述化合物和组合物可用于抑制组蛋白去甲基化酶。此外，所述化合物和组合物可用于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。
• Histone demethylase inhibitors
  申请人：Quanticel Pharmaceuticals, Inc.

  公开号：US08952151B2

  公开（公告）日：2015-02-10

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明涉及治疗癌症和肿瘤性疾病的组合物和方法。提供了替代的氨基吡啶或氨基吡嗪衍生物化合物和含有该化合物的制药组合物。这些化合物和组合物对于抑制组蛋白去甲基化酶非常有用。此外，这些化合物和组合物对于治疗癌症非常有用，例如前列腺癌，乳腺癌，膀胱癌，肺癌和/或黑色素瘤等。